Autopsy report · NCT04761848

Evaluation the Safety and Efficacy of Cilostazol in Treatment of Patients With Fatty Liver Disease

“Institutional and funding constrains”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1, Phase 2

Sponsor

Sadat City University

Sponsor type

University, hospital or other

Conditions

Fatty Liver, Nonalcoholic

Interventions

Cilostazol 50 MG; Placebo

Participants

0

Sites

1

Countries

Egypt

Trials that died the same way

• Pilot Study of the Sage Guard for Oral Cavity Protection
  “Funding constraints” (79% match in meaning)
• A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib
  “Funding issues” (70% match in meaning)
• Anti-rheumatic Drug Use and Risk of COVID-19 Infection in Rheumatoid Arthritis Patients
  “Institutional Issue” (70% match in meaning)
• Thrust Versus Non-thrust Manipulation in Chronic Low Back Pain
  “Time and funding constraints” (69% match in meaning)
• Amplification of Positivity for Alcohol Use Disorder Co-Occurring With Anxiety or Depression
  “Limited funding” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.